How to Save Money on Skyrizi in 2026: Coupons, Discounts, and Patient Assistance

Skyrizi (risankizumab) is one of the most effective biologics available for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis—but it comes with a price tag to match. The list price of a single Skyrizi dose is approximately $22,000, and for maintenance therapy given every 8–12 weeks, the annual cost without coverage can exceed $70,000–$90,000. The good news: most patients who are prescribed Skyrizi can access significant savings through AbbVie's support programs, insurance, and other resources. Here's everything available in 2026.

What Does Skyrizi Actually Cost in 2026?

The list (WAC) price for Skyrizi is approximately $22,383 per dose as of early 2025, according to AbbVie. For plaque psoriasis and PsA patients receiving 150 mg every 12 weeks, that's roughly 4–5 doses per year, putting the gross annual cost above $90,000. For IBD patients on 8-week maintenance cycles, costs are even higher. However, the list price is rarely what patients pay when insurance, co-pay cards, or patient assistance programs are involved.

Option 1: Skyrizi Complete Savings Card (Commercial Insurance Patients)

The Skyrizi Complete Savings Card is the most powerful tool available to patients with commercial (private) insurance. Eligible patients may pay as little as $0 per quarterly dose with this card. Here's how it works:

Available to patients with commercial insurance coverage for Skyrizi who meet eligibility criteria

Not available to patients with Medicare, Medicaid, TRICARE, or other government-funded insurance programs

Also covers certain associated lab tests not fully covered by insurance (maximum $1,000/year for lab costs)

For IBD patients: also covers Skyrizi-associated infusion costs (subject to terms)

Savings limits may apply if your insurance has an accumulator adjustment or co-pay maximizer program

To enroll: call 1-866-SKYRIZI (1-866-759-7494), visit SKYRIZISavingsCard.com, or enroll through the Skyrizi Complete program.

Option 2: myAbbVie Assist (Uninsured or Underinsured Patients)

If you are uninsured, underinsured, or have Medicare Part D and cannot afford Skyrizi, the myAbbVie Assist Patient Assistance Program may provide your medication at no cost if you meet income and eligibility requirements.

Eligibility requirements for myAbbVie Assist:

U.S. resident or U.S. territory resident

Being treated by a licensed U.S. healthcare provider on an outpatient basis

Limited or no health insurance coverage and demonstrated financial need

Medicare Part D enrollees must show denial of eligibility for the Extra Help low-income subsidy

To apply: visit AbbVie.com/PatientAccessSupport, call 1-800-222-6885, or ask your doctor's office to help complete the application (requires provider signature and income documentation).

Option 3: AbbVie's Bridge Program (Insurance Delays or Denials)

If your insurance approval is delayed more than 5 business days—or if your initial prior authorization is denied—AbbVie's bridge program through Skyrizi Complete can provide your medication at no charge while you're working through the insurance process. This program runs for up to 2 years or until insurance approval is obtained, whichever comes first. Eligibility: commercially insured patients ≤63 years old with a valid Skyrizi prescription and a PA denial on file with a confirmed appeal.

Option 4: Patient Access Network (PAN) Foundation (Medicare Patients)

Medicare patients who need financial assistance with Skyrizi out-of-pocket costs may qualify for grants through the Patient Access Network (PAN) Foundation's Inflammatory Bowel Disease fund, which offers up to $4,000 annually in cost assistance. Grant availability depends on fund status. Contact PAN Foundation at panfoundation.org or 1-866-316-7263.

Option 5: Insurance Coverage and Negotiated Rates

With commercial insurance, Skyrizi is typically covered as a specialty-tier drug (Tier 4 or 5) with prior authorization. Once approved, your co-pay or coinsurance will depend on your specific plan, deductible, and out-of-pocket maximum. For most commercially insured patients using the Skyrizi Complete Savings Card, the net out-of-pocket cost is dramatically reduced—sometimes to $0. With Medicare, Skyrizi is covered under Part B (for physician-administered doses) or Part D (for self-injected doses), with varying co-pays depending on the plan.

Savings Summary: Know Your Options

Commercial insurance + Savings Card: As little as $0 per dose; call 1-866-SKYRIZI

Uninsured/underinsured: myAbbVie Assist provides free medication; call 1-800-222-6885

Insurance delay/denial: AbbVie bridge program (up to 2 years) for eligible commercially insured patients

Medicare patients: PAN Foundation IBD fund (up to $4,000/year, subject to availability)

Once your savings program is sorted out, medfinder can help you locate which pharmacy near you can fill your prescription, so you're not left making calls on your own. Enter your medication, dosage, and location—and medfinder does the work.

For more tips on tracking down your prescription, see How to Find Skyrizi in Stock Near You.